British Columbia COVID-19 Consortium (BCCC), Canada

Registration Status: Completed

Objective: The British Columbia COVID-19 Consortium (BCCC) is designed to facilitate rapid, ethical and equitable collaborative access to biospecimens and data collected from COVID-19 patients in British Columbia. A major biospecimen collection is being assembled from both mild and moderate-severe COVID-19 patients admitted to the Vancouver General Hospital (VGH) and Surrey Memorial Hospital Intensive Care Units (ICU), as well as convalescent and SARS-CoV-2-negative specimens collected from VGH. For ICU patients, arterial blood will be drawn on days 1-10, 14, 21 and clinical follow up in including venous blood collections are planned at 8-10 weeks, 3 months, 6 months, and 12 months after admission for surviving patients. Details of negative and convalescent venipuncture are evolving. The BCCC Biobank will include serum, EDTA-plasma, buffy coat-extracted DNA, peripheral blood mononuclear cells, and a nasal swab. These specimens will be analyzed for several types of biomarkers and, following primary analysis, specimens will be stored for future analyses. The BCCC Biobank will be housed at the Djavad Mowafaghian Centre for Brain Health (DMCBH), University of British Columbia (UBC).

Registered Biobank Name	British Columbia COVID-19 Consortium (BCCC)
Biobank Leader	Cheryl Wellington
Country	Canada
Email for biobank inquiries	cheryl.wellington@ubc.ca
Principal Investigator	Cheryl Wellington, Mypinder Sekhon
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).